CAMBRIDGE, MA, December 7, 2022 -- hC Bioscience, Inc., a pioneer in the development of tRNA-based therapeutics, appointed Martin Maier, Ph.D., to its Scientific Advisory Board. Dr. Maier's background will bring, among other contributions, an expertise in nucleic acid chemistry and delivery, and the development of nucleic acid therapeutics.
“Dr. Maier joins a group of experts spanning basic, translational, and clinical R&D to help guide our development of tRNA-based therapeutics,” said Yosef Landesman, PhD, chief scientific officer of hC Bioscience. “His expertise in delivery of therapeutic nucleic acids will contribute to our ongoing work to optimize the transport of engineered tRNA into cells.”
“hC Bioscience is advancing an elegant therapeutic modality that, in simplified terms, proofreads and repairs typos in RNA that lead to disease-causing proteins,” said Dr. Maier. “The company is executing proof-of-concept experiments for designing and applying tRNAs to ensure correct proteins are manufactured in the cell.”
Dr. Maier currently serves as a Senior Vice President at Alnylam Pharmaceuticals, heading the Oncology group. Dr. Maier, who joined Alnylam in 2006, has contributed to the development of lipid nanoparticles and GalNAc conjugates, two clinically validated platforms for siRNA delivery, as well as the advancement of multiple therapeutic programs to development, which has resulted in the approval of five RNAi therapeutics to date. After receiving his Ph.D. in Organic Chemistry in 1997 at the University of Tübingen, Germany, Martin moved to the U.S. for his postdoctoral research at Ionis Pharmaceuticals, where he subsequently assumed a permanent position working on novel chemistries and delivery systems for antisense oligonucleotides.
